Next generation proteasome inhibitors

Bookmark and Share
Published: 16 Jul 2010
Views: 7325
Rating:
Save
Dr Keith Stewart - Mayo Clinic, Arizona, USA
Dr Stewart discusses results of Phase I and Phase II trials of carfilzomib, a next generation proteasome inhibitor, which has a different binding structure to bortezomib.

This interview is supported by an unrestricted educational grant from Novartis Oncology.

15th Congress of the European Hematology Association (EHA), 10—13 June, 2010, Barcelona

Interview with Dr Keith Stewart (Mayo Clinic, Arizona, USA )

Next generation proteasome inhibitors
           
You’re going to talk about second, third generation proteasome inhibitors at this meeting in Barcelona.

I’m going to talk about Carfilzomib, it’s a new class of proteasome inhibitor.  It has a different binding structure to the proteasome as compared to Bortezomib, which is the sort of primary drug.  The result of that different structure is it binds irreversibly to the proteasome and has sustained deeper and probably more specific proteasome inhibition. 

Is that going to do you any harm being irreversible?

The concern when we started the trials of the drug was that we didn’t know if these were good or bad things.  It may mean it’s more toxic and less efficient because it’s more specific or it could be the opposite and I think fortunately it’s the opposite, so it appears to be less toxic and probably as effective, or slightly more.

Any neuropathy?

Well, I shouldn’t say zero; it is minimal.

So how do you explain that?

Well, we think that it probably shows that the neuropathy from Bortezomib is off target.

It’s not related to the proteasome inhibition?

We don’t think so any more because even in animal studies Carfilzomib, they both inhibit the proteasome very efficiently yet Carfilzomib, with animal studies and in man, does not appear to be associated with the severe neuropathy that one can see with Bortezomib.

Have you done Phase I and Phase II trials?

Phase I we did; that established a safe dose and showed that you could give this drug with effectiveness.  The response rates in Phase I myeloma trials were in the 20% range. And then subsequently Phase II trials were done both in Bortezomib resistant and in Bortezomib naïve patients.  What we’ll present at this meeting is the Bortezomib naïve population primarily.  The response rate in the Bortezomib resistant population is about 13% partial response, 20% clinical benefit, so it’s not dramatic but there are some patients who will still respond.   The primary benefit seems to be or the primary most effective data is in Bortezomib naïve patients where we will show that the response rate is 55% partial response or better which is probably the highest ever for a single agent in myeloma.

Is the next stop combination treatments?

Combination’s already underway.  Carfilzomib plus Revlimid plus Dexamethasone is a poster at this meeting; safe, looks effective.  An international randomised Phase III trial for registration purposes, is starting within the next month in a large number of countries, recruiting 700 patients. 

What’s the standard arm?

The standard arm is Revlimid plus low dose Dexamethasone , which is a standard for relapse versus Carfilzomib plus Revlimid and low dose Dexamethasone plus Revlimid.  The drug has now moved into the newly diagnosed patient arena with some investigator sponsored trials in newly diagnosed patients combined with Revlimid or with cyclophosphamide.

What else is new in myeloma?

Pomalidomide is new.  Pomalidomide is a third generation thalidomide.  It has a  chemical structure related to Revlimid and Thalidomide; it is also profoundly active with about 50% response rate in early stage and 30%, even in patients who are refractory to Revlimid, which is very interesting, so probably a more potent drug than we currently have available but with a side effect profile that looks somewhat like Revlimid.

Related Videos

The advances in the management of patients with Hodgkin lymphoma and non-Hodgkin...
Dr Eduardo Sotomayor - H. Lee Moffitt Cancer Center & Research Institute, Florid...
The advances in the management of patients with Hodgkin lymphoma and non-Hodgkin lymphoma ( Dr Eduardo Sotomayor - H. Lee Moffitt Cancer Center & Research Institute, Florida, USA )
9 Jul 2022
Axicabtagene ciloleucel provides superior EFS vs standard of care in elderly wit...
Dr Anna Sureda - Blood Cell Barcelona Hematology Institute, Barcelona, Spain
Axicabtagene ciloleucel provides superior EFS vs standard of care in elderly with relapsed/refractory large B-cell lymphoma ( Dr Anna Sureda - Blood Cell Barcelona Hematology Institute, Barcelona, Spain )
1 Jul 2022
Ibrutinib plus venetoclax for 1-L treatment of CLL and small lymphocytic lymphom...
Dr Carol Moreno - University of Barcelona, Barcelona, Spain
Ibrutinib plus venetoclax for 1-L treatment of CLL and small lymphocytic lymphoma shows a clinically meaningful PFS ( Dr Carol Moreno - University of Barcelona, Barcelona, Spain )
21 Jun 2022
CAR-T cell therapy targeting BCMA is highly effective for patients with relapsed...
Dr Carlos Fernández De Larrea - Hospital Clínic de Barcelona, Spain
CAR-T cell therapy targeting BCMA is highly effective for patients with relapsed/refractory multiple myeloma ( Dr Carlos Fernández De Larrea - Hospital Clínic de Barcelona, Spain )
14 Jun 2022
A bispecific antibody talquetamab shows promising efficacy in relapsed/refractor...
Prof Monique Minnema - University Medical Center Utrecht, Utrecht, Netherlands
A bispecific antibody talquetamab shows promising efficacy in relapsed/refractory multiple myeloma ( Prof Monique Minnema - University Medical Center Utrecht, Utrecht, Netherlands )
13 Jun 2022
Ponatinib and blinatumomab shows complete molecular response for patients with P...
Dr Nicholas Short - MD Anderson Cancer Center, Houston, USA
Ponatinib and blinatumomab shows complete molecular response for patients with Philadelphia chromosome-positive ALL ( Dr Nicholas Short - MD Anderson Cancer Center, Houston, USA )
13 Jun 2022
Subcutaneous isatuximab administration in combination with pomalidomide-dexameth...
Prof Hang Quach - St.Vincent’s Hospital, Sydney, Australia
Subcutaneous isatuximab administration in combination with pomalidomide-dexamethasone in RRMM can improve convenience and relieve burden for patients ( Prof Hang Quach - St.Vincent’s Hospital, Sydney, Australia )
13 Jun 2022
Targeted therapy combinations with venetoclax superior to chemoimmunotherapy in ...
Prof Barbara Eichhorst - The University of Cologne, Cologne, Germany
Targeted therapy combinations with venetoclax superior to chemoimmunotherapy in frontline CLL ( Prof Barbara Eichhorst - The University of Cologne, Cologne, Germany )
13 Jun 2022
A novel CAR-T cell therapy targeting BCMA is highly effective for patients with ...
Dr Carlos Fernández De Larrea - Hospital Clínic de Barcelona, Barcelona, Spain
A novel CAR-T cell therapy targeting BCMA is highly effective for patients with relapsed/refractory multiple myeloma ( Dr Carlos Fernández De Larrea - Hospital Clínic de Barcelona, Barcelona, Spain )
13 Jun 2022